Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Clinical trial NCT03315026 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03315026
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-14
- Primary completion
- 2026-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.